Search results for "METHOTREXATE"

showing 10 items of 111 documents

Conservative treatment of ectopic pregnancies using a single echo-guided injection of methotrexate into the gestational sac

1991

The authors describe the possibility of the conservative treatment of five early ectopic pregnancies. A single injection of methotrexate into the tubal gestational sac was performed under vaginal ultrasound guidance. In all five cases, a clear ectopic gestational sac could be visualized. The pregnancies dated from the 5th to the 7th week of amenorrhea. Strict ultrasound follow-up following injection showed a gradual reduction in the size of the tubal gestational sac. At the same time, plasma beta-hCG gradually decreased to zero after a maximum time period of 25 days. Subsequent hysterosalpingography performed on all of the women demonstrated bilateral normal patent tubes. It is concluded th…

Infertilitymedicine.medical_specialtyRadiological and Ultrasound Technologymedicine.diagnostic_testEctopic pregnancybusiness.industryObstetricsIncidence (epidemiology)UltrasoundGestational sacObstetrics and GynecologyGeneral Medicinemedicine.diseaseSurgerymedicine.anatomical_structureReproductive MedicinemedicineRadiology Nuclear Medicine and imagingAmenorrheaMethotrexateHysterosalpingographymedicine.symptombusinessmedicine.drugUltrasound in Obstetrics and Gynecology
researchProduct

Evidence of competitive inhibition of methotrexate absorption by leucovorin calcium in rat small intestine

1997

Abstract The effect of leucovorin calcium on the intestinal absorption of methotrexate in rat small intestine was investigated using an in situ rat gut technique. First, the kinetic absorption in situ parameters for methotrexate in solution were obtained: V m =21.54 (±2.22) μ M/h; K m =10.51 (±1.08) μ M; k a =0.26 (±0.03) h −1 and AIC=−188.63. The inhibitory effect of leucovorin calcium in methotrexate intestinal absorption has been investigated by perfusing of 10 μ M methotrexate isotonic solutions containing increasing concentrations of leucovorin calcium (10–500 μ M), and the remaining concentrations of both compounds were measured. A competitive inhibition of methotrexate absorption was…

Leucovorin CalciumChemistryReabsorptionPharmaceutical SciencePharmacologyIntestinal absorptionSmall intestineExcretionNon-competitive inhibitionmedicine.anatomical_structurePharmacokineticsmedicineMethotrexatemedicine.drugInternational Journal of Pharmaceutics
researchProduct

Prodrug based on halloysite delivery systems to improve the antitumor ability of methotrexate in leukemia cell lines

2021

The prodrug approach, as well as the development of specific systems able to deliver a chemotherapeutic agent in the target site, decreasing the side effects often associated with its administration, are still a challenging. In this context, both methotrexate drug molecules (MTX) and biotin ligand moieties, whose receptors are overexpressed on the surface of several cancer cells, were loaded on halloysite nanotubes (HNTs) to develop nanomaterial based on multifunctional and "smart" delivery systems. To highlight the crucial role played by biotin, carrier systems based on HNTs and MTX were also synthetized. In detail, several approaches were envisaged: i) a supramolecular interaction between…

LeukemiaNanotubesHalloysite nanotubesBiotinAntineoplastic AgentsSurfaces and InterfacesGeneral MedicineSettore CHIM/06 - Chimica OrganicaCell LineDrug delivery systemsColloid and Surface ChemistryMethotrexateSpectroscopy Fourier Transform InfraredSettore BIO/14 - FarmacologiaClayHumansProdrugsPhysical and Theoretical ChemistryLeukemia cellsProdrugBiotechnologySettore CHIM/02 - Chimica Fisica
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

An in vitro and in vivo study of peptide-functionalized nanoparticles for brain targeting: The importance of selective blood-brain barrier uptake

2017

Targeted delivery of drugs across endothelial barriers remains a formidable challenge, especially in the case of the brain, where the blood-brain barrier severely limits entry of drugs into the central nervous system. Nanoparticle-mediated transport of peptide/protein-based drugs across endothelial barriers shows great potential as a therapeutic strategy in a wide variety of diseases. Functionalizing nanoparticles with peptides allows for more efficient targeting to specific organs. We have evaluated the hemocompatibilty, cytotoxicity, endothelial uptake, efficacy of delivery and safety of liposome, hyperbranched polyester, poly(glycidol) and acrylamide-based nanoparticles functionalized wi…

Male0301 basic medicinePharmaceutical ScienceMedicine (miscellaneous)LIPOSOMES02 engineering and technologyPharmacologyDrug Delivery SystemsTissue DistributionGeneral Materials ScienceDENDRIMERSDRUG-DELIVERYCytotoxicityDrug CarriersLiposomeBrain021001 nanoscience & nanotechnologyMETHOTREXATEmedicine.anatomical_structureBlood-Brain BarrierDrug deliveryMolecular MedicineNanomedicine0210 nano-technologyMaterials scienceBiomedical EngineeringBioengineeringBlood–brain barrierMEDIATED TRANSPORTCell Line03 medical and health sciencesIn vivomedicineAnimalsHumansAmino Acid SequenceRats WistarDENDRITIC POLYMERSTargetingSENSITIVE HYDROGELSBiological TransportIn vitron/a OA procedure030104 developmental biologyNANOGELSNanoparticles for drug delivery to the brain80-COATED POLYBUTYLCYANOACRYLATE NANOPARTICLESCELLSNanoparticlesPeptides
researchProduct

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

2015

Introduction This work was undertaken to delineate intracellular signaling pathways for the PDE4 inhibitor apremilast and to examine interactions between apremilast, methotrexate and adenosine A2A receptors (A2AR). Methods After apremilast and LPS incubation, intracellular cAMP, TNF-α, IL-10, IL-6 and IL-1α were measured in the Raw264.7 monocytic murine cell line. PKA, Epac1/2 (signaling intermediates for cAMP) and A2AR knockdowns were performed by shRNA transfection and interactions with A2AR and A2BR, as well as with methotrexate were tested in vitro and in the murine air pouch model. Statistical differences were determined using one or two-way ANOVA or Student’s t test. The alpha nominal…

MaleAdenosineReceptor Adenosine A2AImmunologyBlotting WesternAdenosine A2A receptorGene ExpressionPharmacologyBiologyCell LineMiceRheumatologyPhenethylaminesmedicineCyclic AMPImmunology and AllergyAnimalsGuanine Nucleotide Exchange FactorsReceptorIC50ArtritisReverse Transcriptase Polymerase Chain ReactionTumor Necrosis Factor-alphaMacrophagesAdenosineMolecular biologyCyclic AMP-Dependent Protein KinasesThalidomideMethotrexateMechanism of actionAntirheumatic AgentsCytokinesTumor necrosis factor alphaRNA InterferenceApremilastPhosphodiesterase 4 Inhibitorsmedicine.symptomInflammation MediatorsIntracellularMedicamentsmedicine.drugResearch Article
researchProduct

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)

2017

Leukemia : normal and malignant hemopoiesis 31(4), 846-852 (2017). doi:10.1038/leu.2016.334

MaleCancer Researchmedicine.medical_specialtyLymphomaPopulationMedizinProcarbazineGastroenterologyCentral Nervous System Neoplasms03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImmunologic FactorseducationAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overeducation.field_of_studyHematologybusiness.industryRemission InductionPrimary central nervous system lymphomaHematologyLomustinemedicine.diseaseSurgeryTumor BurdenMethotrexateTreatment OutcomeOncology030220 oncology & carcinogenesisCytarabineQuality of LifeMethotrexateRituximabOriginal ArticleFemalebusiness030215 immunologymedicine.drugLeukemia
researchProduct